Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence
- PMID: 15966752
- DOI: 10.2165/00003088-200544070-00001
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence
Abstract
Buprenorphine is a semi-synthetic opioid derived from thebaine, a naturally occurring alkaloid of the opium poppy, Papaver somniferum. The pharmacology of buprenorphine is unique in that it is a partial agonist at the opioid mu receptor. Buprenorphine undergoes extensive first-pass metabolism and therefore has very low oral bioavailability; however, its bioavailability sublingually is extensive enough to make this a feasible route of administration for the treatment of opioid dependence. The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours. Buprenorphine has a large volume of distribution and is highly protein bound (96%). It is extensively metabolised by N-dealkylation to norbuprenorphine primarily through cytochrome P450 (CYP) 3A4. The terminal elimination half-life of buprenorphine is long and there is considerable variation in reported values (mean values ranging from 3 to 44 hours). Most of a dose of buprenorphine is eliminated in the faeces, with approximately 10-30% excreted in urine. Naloxone has been added to a sublingual formulation of buprenorphine to reduce the abuse liability of the product. The presence of naloxone does not appear to influence the pharmacokinetics of buprenorphine. Buprenorphine crosses the placenta during pregnancy and also crosses into breast milk. Buprenorphine dosage does not need to be significantly adjusted in patients with renal impairment; however, since CYP3A activity may be decreased in patients with severe chronic liver disease, it is possible that the metabolism of buprenorphine will be altered in these patients. Although there is limited evidence in the literature to date, drugs that are known to inhibit or induce CYP3A4 have the potential to diminish or enhance buprenorphine N-dealkylation. It appears that the interaction between buprenorphine and benzodiazepines is more likely to be a pharmacodynamic (additive or synergistic) than a pharmacokinetic interaction. The relationship between buprenorphine plasma concentration and response in the treatment of opioid dependence has not been well studied. The pharmacokinetic and pharmacodynamic properties of buprenorphine allow it to be a feasible option for substitution therapy in the treatment of opioid dependence.
Similar articles
-
Voriconazole greatly increases the exposure to oral buprenorphine.Eur J Clin Pharmacol. 2018 Dec;74(12):1615-1622. doi: 10.1007/s00228-018-2548-8. Epub 2018 Aug 30. Eur J Clin Pharmacol. 2018. PMID: 30167757 Clinical Trial.
-
The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.Pain Med. 2019 Jan 1;20(1):143-152. doi: 10.1093/pm/pnx321. Pain Med. 2019. PMID: 29309700
-
Buprenorphine for cancer pain: is it ready for prime time?Am J Hosp Palliat Care. 2015 Dec;32(8):881-9. doi: 10.1177/1049909114547227. Epub 2014 Aug 27. Am J Hosp Palliat Care. 2015. PMID: 25163678 Review.
-
High-dose buprenorphine: perioperative precautions and management strategies.Anaesth Intensive Care. 2005 Feb;33(1):17-25. doi: 10.1177/0310057X0503300104. Anaesth Intensive Care. 2005. PMID: 15957687 Review.
-
Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.Clin Pharmacokinet. 2004;43(5):329-40. doi: 10.2165/00003088-200443050-00005. Clin Pharmacokinet. 2004. PMID: 15080765 Clinical Trial.
Cited by
-
Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.Pharmaceutics. 2024 Mar 8;16(3):375. doi: 10.3390/pharmaceutics16030375. Pharmaceutics. 2024. PMID: 38543269 Free PMC article.
-
Dysphagia as a Missing Link Between Post-surgical- and Opioid-Related Pneumonia.Lung. 2024 Apr;202(2):179-187. doi: 10.1007/s00408-024-00672-8. Epub 2024 Mar 27. Lung. 2024. PMID: 38538927 Free PMC article.
-
Characterization of a Nonselective Opioid Receptor Functional Antagonist: Implications for Development as a Novel Opioid Dependence Medication.ACS Pharmacol Transl Sci. 2024 Feb 12;7(3):654-666. doi: 10.1021/acsptsci.3c00262. eCollection 2024 Mar 8. ACS Pharmacol Transl Sci. 2024. PMID: 38481688
-
The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults.J Pediatr Pharmacol Ther. 2024;29(1):49-52. doi: 10.5863/1551-6776-29.1.49. Epub 2024 Feb 7. J Pediatr Pharmacol Ther. 2024. PMID: 38332965 Free PMC article.
-
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.Drugs R D. 2023 Dec;23(4):339-362. doi: 10.1007/s40268-023-00443-5. Epub 2023 Nov 8. Drugs R D. 2023. PMID: 37938531 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials